ondansetron has been researched along with Anxiety in 28 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess the effect of ondansetron on symptoms of patients with subjective tinnitus accompanied by sensorineural hearing loss or normal hearing." | 9.17 | Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study. ( Fallah, AY; Hosseini, M; Modabbernia, A; Pourvaziri, A; Taslimi, N; Taslimi, S; Vahidi, H; Yazdani, N; Zarandi, MM, 2013) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 7.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 7.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| "The profile of action of ondansetron was assessed in a novel animal model of anxiety." | 7.69 | Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model. ( Kulkarni, SK; Roychoudhury, M, 1997) |
| "The aim of this study was to assess the effect of ondansetron on symptoms of patients with subjective tinnitus accompanied by sensorineural hearing loss or normal hearing." | 5.17 | Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study. ( Fallah, AY; Hosseini, M; Modabbernia, A; Pourvaziri, A; Taslimi, N; Taslimi, S; Vahidi, H; Yazdani, N; Zarandi, MM, 2013) |
| " In the prelevodopa era, depression and other psychiatric disorders were described in PD, but in untreated patients psychosis was rare." | 4.79 | Parkinson's disease: drug-induced psychiatric states. ( Brown, D; Factor, SA; Molho, ES; Podskalny, GD, 1995) |
| "Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea, anxiety, and insomnia." | 3.88 | Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. ( Lou, G; Wang, W; Zhang, Y, 2018) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 3.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| " In this study, we investigated the effect of MCI-225 in anxiety models in comparison with diazepam, ondansetron, maprotiline, imipramine, and trazodone." | 3.71 | The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism. ( Eguchi, J; Inomata, Y; Saito, K, 2001) |
| "The profile of action of ondansetron was assessed in a novel animal model of anxiety." | 3.69 | Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model. ( Kulkarni, SK; Roychoudhury, M, 1997) |
| " The percentage of reduction of benzodiazepine daily dosage at all time points in the treatment trial was similar for the ondansetron and placebo groups." | 2.69 | A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation. ( Busto, UE; Kaplan, HL; Romach, MK; Sellers, EM; Somer, G, 1998) |
| "Ondansetron pretreatment significantly reduced their plasma cortisol response to m-CPP without affecting the other plasma hormone responses." | 2.68 | Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. ( Baldemore, D; Briggs, NC; Broocks, A; Canter, SK; Hill, JL; Murphy, DL; Pigott, TA; Tolliver, TJ, 1997) |
| "5-Hydroxytryptophan has the opposite effect exacerbating the behavioural response to the aversive situation." | 2.38 | The pharmacology of the 5-HT4 receptor. ( Costall, B; Naylor, RJ, 1993) |
| "Ondansetron was without effect on working memory errors, but significantly increased the number of reference memory errors made by the ex-ethanol group." | 1.29 | The role of 5-HT in the anxiogenic effects of acute ethanol withdrawal and in the long-lasting cognitive deficits. ( al-Farhan, M; Andrews, N; File, SE; Wu, PY, 1993) |
| " These results indicate that distinct and contrasting dose-response profiles exist for these classical and atypical drugs in an animal model of anxiety based on electric shock." | 1.29 | Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test. ( Dooley, DJ; Klamt, I, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 15 (53.57) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lopes, LT | 1 |
| Canto-de-Souza, L | 1 |
| Baptista-de-Souza, D | 1 |
| de Souza, RR | 1 |
| Nunes-de-Souza, RL | 1 |
| Canto-de-Souza, A | 1 |
| Wang, W | 1 |
| Lou, G | 1 |
| Zhang, Y | 1 |
| Nowicki, M | 1 |
| Tran, S | 1 |
| Muraleetharan, A | 1 |
| Markovic, S | 1 |
| Gerlai, R | 1 |
| Gupta, D | 1 |
| Radhakrishnan, M | 1 |
| Kurhe, Y | 2 |
| Mahesh, R | 2 |
| Brüning, CA | 1 |
| Prigol, M | 1 |
| Roehrs, JA | 1 |
| Nogueira, CW | 1 |
| Zeni, G | 1 |
| Hoşten, T | 1 |
| Solak, M | 1 |
| Elemen, L | 1 |
| Ozgun, M | 1 |
| Toker, K | 1 |
| de Oliveira Citó, Mdo C | 1 |
| da Silva, FC | 1 |
| Silva, MI | 1 |
| Moura, BA | 1 |
| Macêdo, DS | 1 |
| Woods, DJ | 1 |
| Fonteles, MM | 1 |
| de Vasconcelos, SM | 1 |
| de Sousa, FC | 1 |
| Taslimi, S | 1 |
| Vahidi, H | 1 |
| Pourvaziri, A | 1 |
| Modabbernia, A | 1 |
| Fallah, AY | 1 |
| Yazdani, N | 1 |
| Taslimi, N | 1 |
| Hosseini, M | 1 |
| Zarandi, MM | 1 |
| Kumar, B | 1 |
| Jindal, A | 1 |
| Pandey, DK | 1 |
| Bhatt, S | 1 |
| Devadoss, T | 1 |
| Schmidt, A | 1 |
| Karlson-Stiber, C | 1 |
| File, SE | 2 |
| Andrews, N | 1 |
| al-Farhan, M | 1 |
| Wu, PY | 1 |
| Rodgers, RJ | 2 |
| Cole, JC | 1 |
| Tredwell, JM | 1 |
| Shepherd, JK | 2 |
| Grewal, SS | 1 |
| Fletcher, A | 1 |
| Bill, DJ | 1 |
| Dourish, CT | 1 |
| Vasar, E | 1 |
| Peuranen, E | 1 |
| Oöpik, T | 1 |
| Harro, J | 1 |
| Männistö, PT | 1 |
| Dooley, DJ | 1 |
| Klamt, I | 1 |
| Factor, SA | 1 |
| Molho, ES | 1 |
| Podskalny, GD | 1 |
| Brown, D | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Bhattacharya, SK | 1 |
| Chakrabarti, A | 1 |
| Sandler, M | 1 |
| Glover, V | 1 |
| Tang, J | 1 |
| Watcha, MF | 1 |
| White, PF | 1 |
| Broocks, A | 1 |
| Briggs, NC | 1 |
| Pigott, TA | 1 |
| Hill, JL | 1 |
| Canter, SK | 1 |
| Tolliver, TJ | 1 |
| Baldemore, D | 1 |
| Murphy, DL | 1 |
| Roychoudhury, M | 1 |
| Kulkarni, SK | 1 |
| Romach, MK | 1 |
| Kaplan, HL | 1 |
| Busto, UE | 1 |
| Somer, G | 1 |
| Sellers, EM | 1 |
| Nowakowska, E | 1 |
| Chodera, A | 1 |
| Kus, K | 1 |
| Eguchi, J | 1 |
| Inomata, Y | 1 |
| Saito, K | 1 |
| Higgins, GA | 1 |
| Jones, BJ | 1 |
| Oakley, NR | 1 |
| Tyers, MB | 1 |
| Randall, JI | 1 |
| Johnston, AL | 1 |
2 reviews available for ondansetron and Anxiety
| Article | Year |
|---|---|
Parkinson's disease: drug-induced psychiatric states.
Topics: Aged; Anxiety; Bipolar Disorder; Clozapine; Depression; Electroconvulsive Therapy; Humans; Levodopa; | 1995 |
The pharmacology of the 5-HT4 receptor.
Topics: 4-Aminobenzoic Acid; 5-Hydroxytryptophan; Animals; Anxiety; Arousal; Brain; Diazepam; Disease Models | 1993 |
5 trials available for ondansetron and Anxiety
| Article | Year |
|---|---|
Ondansetron does not modify emergence agitation in children.
Topics: Anesthesia Recovery Period; Anesthesia, Inhalation; Anesthetics, Inhalation; Anxiety; Child; Child, | 2011 |
Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study.
Topics: Adult; Aged; Anxiety; Depression; Double-Blind Method; Female; Hearing Loss, Sensorineural; Humans; | 2013 |
A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures.
Topics: Activities of Daily Living; Adult; Ambulatory Surgical Procedures; Antiemetics; Anxiety; Conscious S | 1996 |
Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment.
Topics: Adult; Anxiety; Behavior; Blood Pressure; Body Temperature; Euphoria; Female; Heart Rate; Humans; In | 1997 |
A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation.
Topics: Alprazolam; Anti-Anxiety Agents; Anxiety; Double-Blind Method; Female; Humans; Lorazepam; Male; Midd | 1998 |
21 other studies available for ondansetron and Anxiety
| Article | Year |
|---|---|
The interplay between 5-HT
Topics: Animals; Anxiety; Behavior, Animal; Biguanides; Male; Mice; Ondansetron; Periaqueductal Gray; Pipera | 2022 |
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Anxiety; Benzodiazepines; Cisplatin; Depression; De | 2018 |
Serotonin antagonists induce anxiolytic and anxiogenic-like behavior in zebrafish in a receptor-subtype dependent manner.
Topics: Aminopyridines; Animals; Anti-Anxiety Agents; Anxiety; Benzamides; Ketanserin; Ondansetron; Piperazi | 2014 |
Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system.
Topics: Animals; Antidepressive Agents; Antiemetics; Anxiety; Behavior, Animal; Brain; Depression; Depressiv | 2014 |
Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
Topics: Animals; Anxiety; Behavior, Animal; Body Weight; Brain; Citalopram; Corticosterone; Depression; Diet | 2015 |
Involvement of the serotonergic system in the anxiolytic-like effect caused by m-trifluoromethyl-diphenyl diselenide in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain; Dose-Response Relationship, Drug; Female; Lighting; Lo | 2009 |
Reversal of cocaine withdrawal-induced anxiety by ondansetron, buspirone and propranolol.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Buspirone; Cocaine; Male; Motor Activity; O | 2012 |
Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Emotions; Mice; Olfactory Bul | 2012 |
Caffeine poisoning and lactate rise: an overlooked toxic effect?
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antidotes; Anxiety; Caffeine; Central | 2008 |
The role of 5-HT in the anxiogenic effects of acute ethanol withdrawal and in the long-lasting cognitive deficits.
Topics: Animals; Anxiety; Buspirone; Cognition Disorders; Ethanol; Exploratory Behavior; Hippocampus; In Vit | 1993 |
Profile of action of 5-HT3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzamides; Bridged Bicyclo Compounds; Brid | 1995 |
Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Chl | 1994 |
Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.
Topics: Animals; Anxiety; Ceruletide; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Motor | 1993 |
Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Diazepam; Dose-Response Relationship, Drug; Electroshock; Exp | 1993 |
Rat brain monoamine oxidase A and B inhibitory (tribulin) activity during drug withdrawal anxiety.
Topics: Animals; Anxiety; Brain; Brain Chemistry; Cannabis; Ethanol; Isatin; Isoenzymes; Lorazepam; Male; Mo | 1995 |
Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Conflict, Psychological; Diazepam; Disease | 1997 |
An anxiolytic-like effect of ondansetron disappears in oxazepam-tolerant rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Drug Tolerance; Male; Ondansetron; Oxazepam | 1998 |
The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Biguanid | 2001 |
Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists.
Topics: Amygdala; Animals; Anxiety; Conflict, Psychological; Granisetron; Imidazoles; Indazoles; Indoles; Li | 1991 |
Highly potent inhibitory effects of 5-HT3 receptor antagonist, GR38032F, on non-opioid defeat analgesia in male mice.
Topics: Analgesia; Animals; Anxiety; Imidazoles; Male; Mice; Mice, Inbred DBA; Nociceptors; Ondansetron; Rea | 1990 |
Lack of effects of 5HT3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat.
Topics: Animals; Anxiety; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ch | 1989 |